Dihydrosanguinarine exhibits inhibitory effects on K-Ras and TP53 mutant pancreatic cancer cell lines by bidirectionally modulating mut-p53/-Ras and WT-p53/-Ras proteins (Wu et al., 2019). The gene discussed is TP53; the disease is pancreatic neoplasm.